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Background
- SGLT2 inhibitors have been shown to have
a significant benefit for patients with DM2 or
CAD (DAPA-HF, Emperor-reduced)
- The usage of these medications are low
compared to other Goal Directed Medical
Therapy.
- There are multiple contributing factors as to
why these medications are underutilized

Aims For Improvement
Our aim is to assess barriers against
prescription of SGLT2-i at the time of
discharge from TJUH and to increase
utilization after placement on formulary.

Intervention
- Expanding SGLT2-i availability in the
inpatient setting by adding them on
formulary.
- Survey attending level physicians 0n their
SGLT2 inhibitor prescribing practices.
• Develop resources to
promote best practice
guidelines to improve
utilization

• Understand the causes
of SGLT2-I
underutilization at
TJUH

• Compare pre-formulary
and post-formulary
utilization

• Add SGLT2-i to
inpatient formulary

Measurements/ Results

Lessons Learned
Did you meet your aim for improvement?
We determined barriers to inpatient prescription
and saw an increase after the medications was added
on formulary. However, the increase in prescriptions
was not as dramatic as expected.
If not, why not? What will you do or what would
you recommend the next team to in order to
improve on your efforts?
Despite removing the barrier of non-formulary
status for SGLT2-is, there remains a large gap
between patients who have an indication to begin
therapy and those who were appropriately
prescribed it while at TJUH.
If yes, what will your next goal for improvement be
and how will you reach it?

3 new Rx
per 2427
eligible
patients

12 new Rx
per 909
eligible
patients

The next goal is to increase the number of providers
comfortable with prescribing SGLT2-i during an
inpatient stay, in an effort to increase appropriate
prescriptions of SGLT2-i in the inpatient setting.
To do this, we can provide EMR guidelines and
education modules on when to initiate therapy and
to clarify contraindications on inpatient initiation.
What did your team learn about the improvement
process?

Specialty
(No.
Participants)

Comfort Level
Prescribing (1 to 5)
(SDEV)

Most Common Factor
Preventing Initiating as Inpatient

2.75 (1.5)

Unfamiliarity with the evidence for SGLT-2
inhibitors

Endocrinology
(7)

4.86 (0.38)

Preference for outpatient initiation, lack of
availability inpatient

Cardiology (17)

3.29 (1.36)

Cost of medication

Hospital
Medicine (4)

In addition to removing barriers for quality gaps, it
is necessary to actively facilitate changes practicing
trends regarding evolving clinical updates to
optimize patient care.

